Comparative guide · 5 min read

Ginkgo vs Vinpocetine for cognition — circulation-focused nootropics compared

Updated 2026-05-21 · Reviewed by SupplementScore editors · No sponsorships

Read this first. Vinpocetine is a synthetic alkaloid that the FDA has determined is not lawfully marketable as a dietary supplement in the US (April 2019); it has prescription drug status in much of Europe and Russia (Cavinton). Use of OTC vinpocetine in the US is in a legal grey area, and the FDA has specifically warned that it should not be taken by women who are pregnant or could become pregnant. Ginkgo biloba is a botanical with a much larger, but mixed, evidence base.

Both are sold as "cerebrovascular" cognition supports — the marketing pitch is improved cerebral blood flow. Ginkgo biloba (standardised EGb 761 extract) has the much larger evidence base, with a Cochrane review and several large RCTs showing inconsistent but generally modest signals in dementia and age-related cognitive decline. Vinpocetine has a smaller and more methodologically variable trial base, largely from Eastern European pharmaceutical use; meta-analyses have not established convincing benefit. For healthy adults seeking cognitive enhancement, neither has clean evidence.

Quick verdict

Use caseBetter choiceWhy
Healthy adults wanting "more focus"NeitherNeither has clean RCT evidence in cognitively normal users.
Mild cognitive impairment / age-related declineGinkgo EGb 761 (modest case)Larger and longer-duration trials than vinpocetine; effect sizes small and not always replicated.
Dementia (adjunct)Ginkgo EGb 761 (modest)Some signal in subgroups in larger trials; not a substitute for prescribed dementia therapy.
TinnitusGinkgo (modest, mixed)Mixed trial signal in chronic tinnitus; vinpocetine has older Eastern-European trials with less rigorous design.
Vertigo of vascular originGinkgo (modest)The cerebrovascular vertigo indication has some Ginkgo trial support.
Post-stroke cognitive recovery (adjunct)Neither in OTC formBoth are sometimes used clinically in Eastern Europe (Cavinton parenteral) — that's not the OTC supplement context.
Pregnancy / women who could become pregnantAvoid bothFDA explicit warning on vinpocetine; ginkgo has antiplatelet activity and limited pregnancy data.

How they compare on the things that matter

Mechanism — multi-target botanical vs PDE1 inhibitor

Ginkgo biloba extract (standardised EGb 761, 24% flavone glycosides and 6% terpene lactones) is the most-studied form. Mechanisms include platelet-activating factor antagonism, antioxidant activity, modulation of cerebrovascular tone, and modulation of neurotransmitter receptor function. The standardisation matters: studies of unstandardised crude ginkgo cannot be assumed equivalent to EGb 761.

Vinpocetine is a semi-synthetic derivative of vincamine (from Vinca minor). Mechanisms include phosphodiesterase-1 inhibition, voltage-gated sodium channel blockade, and modulation of cerebral microcirculation. The pharmacokinetics involve a short half-life (1–2 hours), poor oral bioavailability (~7%), and CYP-mediated metabolism with documented drug interactions.

Evidence base by clinical endpoint

Practical rule. For a healthy adult seeking cognitive enhancement, neither holds up. If a clinical context exists (mild cognitive impairment, chronic tinnitus, vascular vertigo) and a supplement trial is reasonable alongside proper diagnostic workup, ginkgo EGb 761 240 mg/day is the better-evidenced, better-regulated, easier-to-source option. Vinpocetine has too much regulatory uncertainty, a smaller evidence base, and explicit FDA warnings in pregnancy.

Dose and form

For ginkgo: 120–240 mg/day of standardised EGb 761 extract (24% flavone glycosides, 6% terpene lactones), typically split into two doses. The 240 mg/day dose used in the large GuidAge and GEM dementia trials is the upper end of what trials have studied. Effect on cognition takes months — not a same-day supplement. Crude unstandardised products vary widely and are not interchangeable.

For vinpocetine: trial doses run 15–60 mg/day, split into 3 doses to manage the short half-life. The Eastern European parenteral Cavinton is a different formulation and dose context entirely.

Safety

Ginkgo has clinically meaningful antiplatelet activity. Reported issues include increased bleeding risk (case reports of intracranial haemorrhage in users on warfarin, aspirin, or NSAIDs), interactions with several anticonvulsants, and a 2-week pre-surgery discontinuation recommendation. GI upset and headache are the most common adverse effects. Mass-balance trials have not confirmed serious safety signals at standardised EGb 761 doses, but the bleeding-risk caveat is real and matters clinically.

Vinpocetine has the FDA "should not be taken by pregnant women" position (2019 Federal Register), based on reproductive-toxicity data. Drug interactions occur via CYP-mediated metabolism. Adverse effects include sleep disturbance, dry mouth, headache, dizziness, and transient blood pressure changes. The product quality variation across OTC US vinpocetine supplements has been concerning in independent assays.

What the price difference buys you

Standardised ginkgo (EGb 761 or equivalent verification) runs $0.20–0.50/day at trial doses. OTC vinpocetine runs $0.15–0.40/day. Cost is not the bottleneck. The bottlenecks are the modest evidence and the regulatory grey area for vinpocetine in particular.

Who should skip each

Ginkgo should be approached cautiously in users on anticoagulants, antiplatelets, or NSAIDs, in pregnancy and lactation, in users with seizure disorder (some case reports of seizure aggravation), and discontinued at least 2 weeks before scheduled surgery.

Vinpocetine should be avoided in pregnancy and in women who could become pregnant (explicit FDA position), should be discussed carefully with prescribers in users on multiple medications due to CYP interactions, and approached cautiously in users with cardiovascular disease.

What we'd actually buy

For a clinician-supervised trial in age-related cognitive decline, mild dementia adjunct, or chronic tinnitus: standardised ginkgo (EGb 761 or equivalent verified extract) at 120–240 mg/day for at least 6 months, paired with the standard-of-care plan.

For healthy-adult cognitive enhancement: neither. Better-evidenced cognitive supports for the everyday "more focus" use case are caffeine (low-dose, time-anchored), L-theanine + caffeine, creatine, omega-3, and sleep adequacy.

Sources

Read more: